Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Parkinson’s disease, which is lifelong ... through its $8.7 billion purchase of Cerevel Therapeutics last year. In other late-stage trials, tavapadon showed improvement of symptom control ...

Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

That’s why I’m taking my new medal out for a spin and urging America’s elected leaders to do everything in their power to end Parkinson’s once and for all. Need a break? Play the USA ...

Parkinson's disease is an illness that affects the part of your brain that controls how you move your body. Some people with Parkinson’s first notice weakness, difficulty walking, and stiff muscles.

Roche and partner Prothena are currently the furthest ahead in the field, after starting a phase 2b trial of their prasinezumab candidate in patients with early-stage Parkinson's last year ...

treatment with tavapadon as a monotherapy in adults with early Parkinson's disease. Also Read: Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of ...

Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s ...